Clinical Policy: Alprostadil (Caverject, Edex, Muse)
Reference Number: CP.CPA.02
Effective Date: 11.16.16
Last Review Date: 08.18
Line of Business: Commercial

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Alprostadil (Caverject®, Edex®, Muse®) is a prostaglandin E1 (PGE1) agonist.

FDA Approved Indication(s)
Caverject is indicated:
- For the treatment of erectile dysfunction;
- As an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.

Edex is indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.

Muse is indicated for the treatment of erectile dysfunction. Studies that established benefit demonstrated improvements in success rates for sexual intercourse compared with similarly administered placebo.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Caverject, Edex, and Muse are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Erectile Dysfunction (must meet all):
      1. Member is male;
      2. Age ≥18 years;
      3. Failure of ONE oral Phosphodiesterase Type 5 (PDE5) inhibitor* (e.g., sildenafil) unless contraindicated or clinically significant adverse effects are experienced;
         *Prior authorization is (or may be) required
      4. Dose does not exceed one of the following (a or b):
         a. 60 mcg/dose (Caverject) or 40 mcg/dose (Edex), no more than 3 doses weekly;
         b. Muse: two systems per 24-hour period.
      Approval duration: 6 months or to member’s renewal period, whichever is longer

   B. Other diagnoses/indications:
      1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial.
II. Continued Therapy

A. Erectile Dysfunction (must meet all):
   1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
   2. Member is responding positively to therapy;
   3. If request is for a dose increase, new dose does not exceed one of the following (a or b):
      a. 60 mcg/dose (Caverject) or 40 mcg/dose (Edex), no more than 3 doses weekly;
      b. Muse: two systems per 24-hour period.

Approval duration: 6 months or to member’s renewal period, whichever is longer

B. Other diagnoses/indications (must meet 1 or 2):
   1. Currently receiving medication via health plan benefit and documentation supports positive response to therapy.

   Approval duration: Duration of request or 6 months (whichever is less), or

   2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial or evidence of coverage documents;

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
FDA: Food and Drug Administration
PDE5: Phosphodiesterase Type 5
PGE1: Prostaglandin E1

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cialis® (tadalafil)</td>
<td>Daily: 2.5-5 mg PO QD PRN: 10 mg PO before sexual activity. Dosing range: 5 - 20 mg. The maximum recommended dosing frequency is ONCE per day.</td>
<td>QD dosing (5 mg/day) PRN dosing (20 mg/day)</td>
</tr>
<tr>
<td>sildenafil (Viagra®)</td>
<td>50 mg PO 1 hour (0.5-4 hours) before sexual activity. Dosing range: 25-100 mg. The maximum recommended dosing frequency is ONCE per day.</td>
<td>100 mg/day</td>
</tr>
</tbody>
</table>
Alprostadil

<table>
<thead>
<tr>
<th>Drug Name (Brand name®)</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alprostadil (Caverject)</td>
<td>Initial dosage titration should be done in the physician’s office. Dosage range: 1.25 - 60 mcg intracavernosally prior to sexual activity. The recommended frequency of injection is no more than 3 times weekly, with at least 24 hours between each dose.</td>
<td>60 mcg/dose, with at least 24 hours between doses, and no more than 3 doses weekly</td>
</tr>
<tr>
<td>Alprostadil (Edex)</td>
<td>Initial dosage titration should be done in the physician’s office. Dosage range: 1.25 - 40 mcg intracavernosally prior to sexual activity. The recommended frequency of injection is no more than 3 times weekly, with at least 24 hours between each dose.</td>
<td>40 mcg/dose, with at least 24 hours between doses, and no more than 3 doses weekly</td>
</tr>
<tr>
<td>Alprostadil (Muse)</td>
<td>Initial: 125 - 250 mcg. Titrate on separate occasions to lowest dose required to achieve an erection sufficient for sexual intercourse.</td>
<td>2 systems per 24 hour period</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications

- Men who have conditions that predispose them to priapism, such as sickle cell anemia or sickle cell trait, multiple myeloma, or leukemia.
- Men with fibrotic conditions of the penis, such as anatomical deformation, angulation, cavernosal fibrosis, or Peyronie’s disease.
- Men with penile implants.
VI. Product Availability

<table>
<thead>
<tr>
<th>Drug</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alprostadil</td>
<td>Dry lyophilized powder vials: 20 mcg, 40 mcg</td>
</tr>
<tr>
<td>(Caverject)</td>
<td>Impulse syringe kits, freeze-dried powder in a dual-chamber syringe: 10 mcg</td>
</tr>
<tr>
<td></td>
<td>20 mcg</td>
</tr>
<tr>
<td>Alprostadil</td>
<td>Kits (with diluent): 10 mcg, 20 mcg, 40 mcg</td>
</tr>
<tr>
<td>(Edex)</td>
<td></td>
</tr>
<tr>
<td>Alprostadil</td>
<td>Urethral pellet system: 125 mcg, 250 mcg, 500 mcg, 1000 mcg</td>
</tr>
<tr>
<td>(Muse)</td>
<td></td>
</tr>
</tbody>
</table>

VII. References


Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Converted to new template; added contraindications to “Coverage is Not Authorized For” section for 1) Patients who have conditions that might predispose them to priapism, such as sickle cell anemia or trait, multiple myeloma, or leukemia, 2) Patients with anatomical deformation of the penis, such as angulation, cavernosal fibrosis, or Peyronie’s disease, 3) Patients with penile implants</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.13.17</td>
<td>8.17</td>
<td></td>
</tr>
<tr>
<td>3Q 2018 annual review: added Muse to policy (previously CP.CPA.70); removed off-label use for severe peripheral arterial occlusive disease; removed contraindications in section III as these do not satisfy safety approach for objectively confirmed conditions the result in serious adverse reactions; references reviewed and updated.</td>
<td>05.08.18</td>
<td>08.18</td>
</tr>
</tbody>
</table>

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and
accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright
or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.